* * * * * * * * * * * * * * * * * * * * * * * * * * * * * NOTICE OF GRANT AWARD * * * * * * * * * * * * * * * * * * * * * * ** *

Exhibit 10.35

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * NOTICE OF GRANT AWARD * * * * * * * * * * * * * * * * * * * * * * * * *

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

Grant Number: 1 U01 AI057264-01 (Revised)

Principal Investigator: Krieg, Arthur M. MD

Project Title: Pulmonary innate immune activation for bioterror defense

VP & CONTROLLER

COLEY PHARMACEUTICAL GROUP, INC

93 WORCESTER STREET, STE 101

WELLESLEY, MA 02481

UNITED STATES

Budget Period: 09/15/2003 - 02/29/2004

Project Period: 09/15/2003 - 02/28/2006

Dear Business Official:

The National Institutes of Health hereby revises this award to reflect an increase in the amount of $46,248 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to COLEY PHARMACEUTICAL GROUP, INC. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to terms and conditions referenced below.

Acceptance of this award including the Terms and Conditions is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Award recipients are responsible for reporting inventions derived or reduced to practice in the performance of work under this grant. Rights to inventions vest with the grantee organization provided certain requirements are met and there is acknowledgement of NIH support. In addition, recipients must ensure that patent and license activities are consistent with their responsibility to make unique research resources developed under this award available to the scientific community, in accordance with NIH policy. For additional information, please visit http://www.iedison.gov.

If you have any questions about this award, please contact the individual(s) referenced in the information below.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

See additional information below

SECTION I - AWARD DATA - 1 U01 AI057264-01 (Revised)

AWARD CALCULATION (U.S. Dollars):

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project, is as follows.

FISCAL INFORMATION:

CFDA Number: 93.855

EIN: 1061506689A1

Document Number: UAI057264A

NIH ADMINISTRATIVE DATA:

PCC: I2B / OC: 41.4L /Processed: GORDONJ 040616 0102

SECTION II - PAYMENT/HOTLINE INFORMATION - 1 U01 AI057264-01 (Revised)

For Payment and HHS Office of Inspector General Hotline Information, see the NIH Home

Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III - TERMS AND CONDITIONS - 1 U01 AI057264-01 (Revised)

This award is based on the application submitted to, and as approved by, the NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Grant Award.

b. The restrictions on the expenditure of federal funds in appropriations acts, to the extent those restrictions are pertinent to the award.

c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.

d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(see NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

Treatment of Program Income:

Additional Costs

SECTION IV - NIAID SPECIFIC TERMS OF AWARD -

REVISED AWARD: This revised Notice of Grant Award (NGA) is issued to adjust facilities and administrative (F&A) costs to reflect the negotiated F&A rate dated 04/27/2004. Future year has been adjusted.

Supersedes NGA issued 03/03/2004.

* * * * * * * * * * * * * *

Direct costs awarded are based at the committed level.

This award is subject to the Terms and Conditions of Award as set forth in the SPECIAL REQUIREMENTS section of RFA/PA AI-03-025, NIH Guide to Grants and Contracts, 11/14/2002. These special terms and conditions are incorporated in this award by reference.

Copies of the RFA may be accessed at the following Internet address: http://www.nih.gov/grants/guide/index.html

None of the funds in this award shall be used to pay the salary of an individual at a rate in excess of Executive Level I of the Federal Executive Payscale. The application for this project proposed a salary at a rate greater than Executive Level I per year for Dr. KRIEG and DR. TITBALL. This award and future year commitments have been adjusted accordingly.

David B. Winter, Program Official

Phone: 301 ###-###-#### Email: ***@*** Fax: 301 ###-###-####

Jeannette Gordon, Grants Specialist

Phone: 301 ###-###-#### Email: ***@*** Fax: 301 ###-###-####

SPREADSHEET

GRANT NUMBER: 5 U01 AI057264-02 (Revised)

P.I.: Krieg, Arthur M.

INSTITUTION: COLEY PHARMACEUTICAL GROUP, INC.